Toronto Ottawa Heart Summit - Heart Failure Update


University of Toronto Faculty

David Cherney, CM, PhD, MD, FRCPC
Following his clinical training in Nephrology, Dr. Cherney completed his PhD in human renal physiology at the Institute of Medical Science, University of Toronto in 2008. He is currently Professor in the Department of Medicine, University of Toronto and a Clinician Scientist at the University Health Network and Mount Sinai Hospitals, where he is director of the Renal Physiology Laboratory. He is supported by the Canadian Institutes of Health Research, the JDRF, the Heart and Stroke Richard Lewar Centre of Excellence, the Heart and Stroke Foundation of Canada and the Banting and Best Diabetes Centre. He is also supported by a Department of Medicine, University of Toronto Merit Award. Dr. Cherney’s research program focuses on physiological factors that initiate renal disease in patients with diabetes, such as renal hyperfiltration and inflammation, and the role of the cardiorenal axis in diabetes. His research group is also involved in early and late phase clinical trials in the cardiorenal-metabolic field, including several primary renal outcome trials in patients with and without diabetes. Dr. Cherney’s research program is closely aligned with his integrated and multidisciplinary cardiac-renal-endocrine clinic at the University Health Network, which maintains a strong emphasis on the prevention of diabetic nephropathy and cardiovascular disease. In 2019, he received the American Society of Nephrology (ASN) Distinguished Researcher Award for outstanding contributions to nephrology. In 2019 he also received the Diabetes Canada/CIHR - Institute of Nutrition Diabetes and Metabolism (INMD) Young Scientist Award.

Satya Dash, MD, PhD, FRCP (Edin), FRCPC
Dr. Dash is an Endocrinologist and Assistant Professor at University Health Network/University of Toronto. He is a clinician-scientist with an interest in obesity and cardiometabolic disease and is the Medical Director of the bariatric program.
He graduated from St. Bartholomew’s & The Royal London school of Medicine (UK) and did his PhD and specialty training at Cambridge followed by a post-doctoral fellowship at Toronto. His current research interests are in understanding the etiology of obesity and cardiometabolic disease and its response to weight loss treatment. He is funded by CIHR, Diabetes Canada, Heart and Stroke Foundation, Banting and Best Diabetes Center and McLaughlin Center.

Michael Farkouh, MD, FRCPC, FACC, FAHA
Dr. Farkouh is the Peter Munk Chair in Multinational Clinical Trials at the Peter Munk Cardiac Centre, Director of the Heart and Stroke/Richard Lewar Centre of Excellence in Cardiovascular Research, Professor and Vice-Chair, Research, Department of Medicine at the University of Toronto. He is a graduate of the Schulich School of Medicine at Western University. Dr. Farkouh completed his internal medicine and cardiology training at the Mayo Clinic and the Icahn School of Medicine at Mount Sinai New York respectively and holds an MSc in Clinical Epidemiology from McMaster University. Prior to his current appointments, he served as the founding director of the Mount Sinai Cardiovascular Clinical Trials Unit in New York City. Dr. Farkouh is internationally known for his work on the management of acute coronary syndromes in the emergency room. He has a special interest and expertise in the field of cardiovascular disease in diabetic patients. He is currently the project officer for numerous clinical trials on questions related to diabetes and heart disease including the NIH-sponsored FREEDOM trial. He chairs the committee on diabetes and heart disease at the Banting and Best Centre and at the University of Toronto. Dr. Farkouh has received the Gold Medal from John Paul II Hospital in Krakow, was elected Teacher of the Year at the Mayo Clinic, and was awarded the Jan J. Kellermann Memorial Award for Cardiovascular Disease Prevention from the International Academy of Cardiology. Dr. Farkouh serves as Associate Editor of the Journal of the American College of Cardiology.

Eric Horlick, MD CM, FRCPC, FSCAI
Dr. Eric Horlick is an interventional cardiologist at the Peter Munk Cardiac Centre and a Professor of Medicine at University of Toronto. He is the inaugural Peter Munk Chair in Structural Heart Disease Intervention. His interests include percutaneous therapies for structural and congenital heart disease and percutaneous valve therapy.
Dr. Horlick has delivered over 500 lectures internationally since joining the Cardiology Division at the Peter Munk Cardiac Centre in 2004. He has published over 170 peer reviewed papers and a dozen book chapters. He co-chairs the annual “Toronto Course on Structural and Congenital Heart Disease Intervention”.

Shaun Goodman, MD, MSc, FRCPC
Dr. Shaun Goodman is a Staff Cardiologist and Associate Head in the Division of Cardiology, Department of Medicine, at St. Michael’s Hospital. He is a Professor and Heart & Stroke Foundation of Ontario (Polo) Chair in the Department of Medicine at the University of Toronto. He is a Consultant to the Canadian Heart Research Centre (CHRC). He is an Adjunct Professor in the Department of Medicine at the University of Alberta and a Co-Director of the Canadian VIGOUR Centre. Based upon his longstanding interest in coronary artery disease (including acute coronary syndromes [ACS]), and secondary prevention therapies, he helped to design, and is an Executive Steering Committee member of, the ODYSSEY OUTCOMES trial examining the role of PCKS9 inhibitor therapy in addition to maximally tolerated statin in post-ACS patients. He will discuss this trial and other key PCSK9 inhibitor studies, together with the role for the cholesterol absorption inhibitor ezetimibe in lowering low-density lipoprotein-cholesterol (LDL-C), and the benefits of inflammation-modifying treatments (icosapent ethyl [IPE], a highly purified eicosapentaenoic acid [EPA] ethyl ester, and low-dose colchicine) in reducing residual atherosclerotic cardiovascular disease risk.

Mark Iwanochko, MD, FRCPC
Dr. Iwanochko is an assistant professor of medicine at the University of Toronto. He is Medical director of the Robert J Burns nuclear cardiology laboratory, and the Centre of Excellence in Nuclear cardiology at the Peter Munk Cardiac Centre. He is trained in Nuclear Cardiology (1997) Diplomate in the Sub-Specialty of Nuclear Cardiology (CBNC. He is the Ontario PI for the Canadian Fabrys Disease Initiative.His area’s of interest include clinical trials, and outcomes research in cardiac imaging. Cardiac involvement in patients with Fabry’s disease.

Lawrence A. Leiter, MDCM, FRCPC, FACP, FACE, FAHA
Dr. Lawrence A. Leiter is Director of the Lipid Clinic; Associate Director of the Clinical Nutrition and Risk Factor Modification Centre; and Associate Scientist, Li Ka Shing Knowledge Institute at St. Michael’s Hospital in Toronto where he was also the Head of the Division of Endocrinology and Metabolism from 2000-2010. He is a Professor in the Departments of Medicine and Nutritional Sciences at the University of Toronto.
Dr. Leiter has several research interests including clinical trials on the prevention of atherosclerosis, especially in diabetes, and the dietary and pharmacologic treatment of diabetes mellitus, hyperlipidemia, hypertension, and obesity. He has over 800 publications in peer-reviewed journals. He was an investigator in many of the landmark diabetes trials including the DCCT, ACCORD, and ADVANCE and has had leadership roles in many past and ongoing outcome trials in both the diabetes and lipid areas. In 2018, 2019, and 2020 he was a Clarivate Analytics Top 1% Highly Cited Researcher.
Dr. Leiter is a Past-President of the Canadian Society of Endocrinology & Metabolism (CSEM) and a past Chair of the Clinical and Scientific Section of the Canadian Diabetes Association (CDA). He has been involved in many national and international committees and consensus conferences including those of the International Diabetes Federation, CDA, Canadian Hypertension Education Program (CHEP), Canadian Cardiovascular Society (Dyslipidemia), and Obesity Canada. He is an Associate Editor of the journal Diabetes Care.
For his work, he has received a number of awards including the CDA Frederick G. Banting Award and the American Diabetes Association Charles H Best Award (awarded to DCCT investigators), both for Distinguished Service, the 2005 CSEM Educator of the Year Award, and the 2006 CDA Gerald S. Wong Award in recognition of significant contributions to the diabetes community. He was the inaugural winner of the St. Michael’s Hospital Complete Physician Award in 2009. He is also the 2016 recipient of both the CDA Lifetime Achievement Award for Research Excellence and the CSEM Robert Volpe Distinguished Service Award. In 2019 was elected as a Fellow of the Canadian Academy of Health Sciences.

Dr. Madan completed her medical training at McGill University. She trained in clinical cardiology at the Ottawa Heart Institute. She trained in interventional cardiology and clinical trials research at Duke University and at the Duke Clinical Research Institute in Durham, North Carolina. During this time, she earned a Masters in Health Sciences in Clinical Research. In 1999, Dr Madan joined the Division of Cardiology at Sunnybrook Health Sciences Centre as an Interventional Cardiologist, and was the Director of Interventional Cardiology Clinical Trials Research from 2006-2019. She is currently the Medical Director of the Cardiac Catheterization Lab for the Schulich Heart program. She is an Associate Professor of Medicine and the Heart & Stroke Foundation Polo Chair in Cardiology at the University of Toronto.
Her main clinical interest is the management and prevention of coronary artery disease. Her research interests have been primarily focused on improving the efficacy, safety, and durability of percutaneous coronary interventions using new pharmacotherapy and devices. Recent projects have focused on secondary prevention, and included the evaluation of cholesterol lowering strategies, and the investigation of new approaches for smoking cessation among acute coronary syndrome patients. In 2019, Dr. Madan launched the Sunnybrook SCAD Clinic, a new subspecialty clinic to coordinate care for survivors of acute myocardial infarction related to spontaneous coronary artery dissection.

Susanna Mak, MD, PhD, FRCPC
Dr. Mak is a Cardiologist and Clinician Scientist at the Lunenfeld Tanenbaum Research Institute, Sinai Health. She is also the Department of Medicine’s Division Director for Cardiology and holds the Dexter HC Man Chair at the University of Toronto. Dr. Mak is the Director of both the Anna Prosserman Heart Function Clinic and the Harold & Esther Mecklinger and The Posluns Family Cardiac Catheterization Research Laboratory at the Mount Sinai Hospital. She completed subspecialty training in the care of advanced heart failure and received her PhD from the Institute of Medical Sciences at the University of Toronto. Dr. Mak is an expert in the assessment of hemodynamics and heart chamber function in humans, and leads a research program in cardiovascular physiology. Dr. Mak’s specific research interests include the contrasts between the cardiovascular physiology of men and women and the pathophysiology of pulmonary arterial hypertension and heart failure. Dr. Mak also leads the program to improve the quality of care for patients with acute and advanced chronic heart failure at Sinai Health. Dr. Mak receives funding from the Heart and Stroke Foundation of Canada, the Ontario Research Fund and the Canadian Institutes for Health Research. The program also gratefully acknowledges the support Miles Nadal and Carol Grafstein among other generous donors to the Sinai Health Foundation.

Philip McFarlane, MD, PhD, FRCPC
Dr. Phil McFarlane is a clinical-investigator in the Division of Nephrology at St. Michael's Hospital in Toronto, and an assistant professor at the University of Toronto. At St. Michael’s he is the Medical Director of Home Dialysis and the Chief Nephrologist in the Live Kidney Donor Program. He is a member of the Diabetes Canada Clinical Practice Guidelines group, the Canadian Society of Nephrology guideline group, and the Hypertension Canada guideline group. He has completed his Ph.D. in health economics at the Institute for Medical Sciences at the University of Toronto. His areas of research interest include health economics and outcomes research. He is currently the Ontario Renal Network Provincial Medical Lead for hemodialysis. He has published over 100 peer-reviewed manuscripts and three book chapters.

Jacob Udell, MD, MPH, FRCPC
Dr. Jay Udell is a Cardiologist and Associate Professor of Medicine and Health Policy, Management and Evaluation at University of Toronto. He is the interim division head of cardiology at Women’s College Hospital and cross appointed at UHN and Sinai Health System. He has expertise in clinical epidemiology and conducting population-based cohort studies with linked administrative health data as well as phase III/IV clinical trials. His clinical and research focus is in primary and secondary prevention of ischemic heart disease and heart failure.

Atul Verma, MD, FRCPC
Dr. Atul Verma is a staff cardiac electrophysiologist and Director of Arrhythmia Services at Southlake Regional Health Care Centre in Newmarket, Ontario, Canada. He is an Associate Professor with the University of Toronto and Adjunct Professor with McGill University. Specific interests include ablation of atrial fibrillation and ventricular tachycardia especially new techniques and technologies.
Dr. Verma has served as Chair or writing member of a number of national and international guideline committees including the Canadian Cardiovascular Society Atrial Fibrillation Guidelines Committee and the HRS Consensus Statement on Catheter Ablation of AF. He has also led many clinical trials in cardiac ablation.
Dr. Verma completed his medical school and cardiology residency at the University of Toronto and then specialized in cardiac electrophysiology at the Cleveland Clinic. He has published over 250 peer-reviewed articles in many journals including the New England Journal of Medicine, JAMA, Lancet, Circulation, JACC, European Heart Journal, and others.

University of Ottawa Faculty

Thais Coutinho, MD
Dr. Thais Coutinho received her medical degree from the Universidade Federal do Rio de Janeiro, in Brazil, in 2004, and completed residency and fellowship training in Internal Medicine, Cardiology, Vascular Medicine, advanced Echocardiography and Research at the Mayo Clinic in Rochester, MN, in 2013.
Upon graduating, Dr. Coutinho joined the University of Ottawa Heart Institute as a Clinician-Scientist. In 2017, she was appointed Chief of the Division of Cardiac Prevention and Rehabilitation and Chair of the Canadian Women's Heart Health Centre. She is also an Associate Professor of Medicine at the University of Ottawa.
She focuses her clinical practice on Preventive Cardiology, Vascular Medicine, Women’s Heart Health and Echocardiography. Her research program focuses on arterial health, with a special emphasis on arterial stiffness and its role on the pathogenesis and sex differences of cardiovascular diseases. To pursue these investigations, she holds several research grants, including an Early Research Leaders Grant and a Grant-in-Aid from the Heart and Stroke Foundation of Canada, a Project Grant from the Canadian Institutes of Heart Research, and a Clinician Scientist Award from the Heart and Stroke Foundation of Ontario.
Dr. Coutinho has received numerous awards, including the American Heart Association’s Young Investigator Award (2011), the Mayo Clinic’s Summerskill Research Award and Cardiovascular Division Outstanding Achievement Award (2013), the Canadian Cardiovascular Society’s Young Investigator Award (2015), the University of Ottawa Heart Institute’s Global Impact Award (2019) and the Women as One Research Award (2021).
Dr. Coutinho is also very active in education and knowledge translation, having addressed numerous audiences nationally and internationally. To further knowledge translation in women’s heart health topics, she has served as Co-Chair of the first (2016), second (2018) and third (2021) Canadian Women's Heart Health Summit, the largest conference in the world dedicated exclusively to the cardiovascular health of women, in addition to launching and Chairing the Canadian Women’s Heart Health Alliance, a national network focused on bridging knowledge and practice gaps pertaining to women’s cardiovascular health issues.

Sharon Chih, MBBS, PhD, FRACP
Dr. Sharon Chih is a heart failure-transplant cardiologist and clinician investigator at the University of Ottawa Heart Institute, and an associate professor of medicine at the University of Ottawa. She is the medical director of the Heart Transplant and Mechanical Circulatory Support Program and co-lead for the Shock Team at the University of Ottawa Heart Institute. Her research interest is in heart transplantation with a focus on cardiac allograft vasculopathy and allosensitization.

Mehrdad Golian, MD, FRCPC
Dr. Mehrdad Golian, MD, is a cardiologist and invasive electrophysiologist at the University of Ottawa Heart Institute.
Dr. Mehrdad Golian completed his medical school training, internal medicine and cardiology residencies at the University of Manitoba. During his residency, he served as a co-chief internal medicine resident. During his cardiology training, he was the chief cardiology resident. Dr. Golian completed his fellowship training in electrophysiology at St. Michael’s Hospital in Toronto where he was highly regarded for his clinical and EP skills, as well as caring interactions with patients and staff.
Dr. Golian was the 2015 recipient of Heart and Stroke Sanofi Aventis award. In 2012, he received the Merk and Sylvia Markel studentship award for academic excellence, research, and patient care.
Dr. Golian’s academic interests are patient safety and quality improvement. His clinical interests include: cardiac resynchronization therapy, electrophysiology study, and ablation for cardiac arrhythmia.

Benjamin Hibbert, MD, PhD, FRCPC
Benjamin Hibbert, MD, PhD, is an Interventional Cardiologist and Director of the Vascular Biology and Experimental Medicine Laboratory. He is also Assistant Professor in the Department of Medicine at the University of Ottawa.
Dr. Hibbert earned his Doctorate in Medicine in 2006, followed by an Internal Medicine residency at the University of Ottawa. He subsequently went on to complete his Cardiology training and the Clinician Investigator Program while obtaining his PhD in Biochemistry – both at the University of Ottawa Heart Institute. Finally, he completed a fellowship in Interventional Cardiology from 2013-2015 with an interest in structural left atrial procedures (ASD & PFO closure, LAA closure, PTMV and Mitraclip). He joined on staff at the University of Ottawa Heart Institute in 2015.
Dr. Hibbert’s clinical interests include both clinical and basic science research projects with a goal of performing truly translational research. His outcome based research has been performed clinically in patients undergoing percutaneous coronary interventions or structural heart disease procedures. Topics of interest include biomarker development, adjuvant pharmacotherapy (antiplatelets, antithrombotics etc.) and impact of device selection on clinical outcomes.
Dr. Hibbert’s laboratory focuses on mechanisms involved in pathologic arterial remodelling in the development of transplant vasculopathy, in-stent restenosis, and atherosclerosis - with a goal of identifying therapeutic targets.

Peter Liu, MD, FRCPC, FACC
Dr. Peter Liu is currently the Chief Scientific Officer and VP of Research of the University of Ottawa Heart Institute, and also Professor of Medicine and Physiology at the University of Toronto and Ottawa. He is the former Scientific Director of the Institute of Circulatory and Respiratory Health at the Canadian Institutes of Health Research, the President of International Society of Cardiomyopathy & Heart Failure of World Heart Federation, and inaugural Director of the Heart & Stroke/Lewar Centre at University of Toronto. He received his MD degree from University of Toronto, and postgraduate training at Harvard University. His laboratory investigates the causes and treatments of heart failure, role of inflammation and identification of novel biomarkers and targets for intervention in cardiovascular diseases. He has published over 400 peer reviewed articles in high impact journals, and received numerous awards in recognition of his research and scientific accomplishments. He has chaired scientific sessions of the Heart Failure Society of America, International Society of Heart Research and Human Proteomic Organization, amongst others. He is also champion for knowledge translation, integrating the cardiovascular prevention guidelines and healthy heart policy in Canada and internationally, including the C-CHANGE guidelines.

Dr. Derek So, a Professor at the University of Ottawa Heart Institute (UOHI), is an interventional cardiologist and program director for the Adult Interventional Cardiology program. He obtained his medical school training at the University of Toronto and completed residency training in internal medicine at McMaster University. He further trained in Cardiology and Interventional Cardiology at UOHI. Dr. So holds a Master’s degree in Clinical Epidemiology from the Harvard School of Public Health.
Dr. So’s research interests include: acute coronary syndromes, PCI outcomes, pharmacogenomics and personalized anti-platelet therapy. Currently, Dr. So is leading a group of basic science and clinical researchers in the RAPID program, studying future strategies for personalized anti-platelet therapy. As part of the RAPID program, Dr. So presented the RAPID GENE study, a late breaking trial at Transcatheter Cardiovascular Therapeutics (TCT) 2011 and published in the LANCET. Dr. So has held multiple grants from the Canadian Institute of Health Research (CIHR) and the Heart and Stroke Foundation (HSF) in the field of anti-platelet therapies, including the RAPID MANAGE, RAPID CABG and RAPID EXTEND studies. In 2016, Dr. So was granted a mid-career investigator award from the Heart and Stroke Foundation of Canada.
Currently, Dr. So is the interventional cardiology lead at the UOHI Code Shock Program, the CHIP program and participates in the UOHI CTO interventional team.

Guest Faculty

Anita W. Asgar, MD, MSc, FRCPC, FACC
Dr Anita Asgar is an Interventional Cardiologist working at the Montreal Heart Institute since 2009. Originally from Newfoundland, Dr. Asgar completed her medical school and Internal Medicine Residency at Memorial University (1995-2002), and Cardiology training at Dalhousie University. She then completed a two-year fellowship in Interventional Cardiology at the Institut de Cardiologie de Montreal, followed by a fellowship in Structural and Congenital Intervention at the Royal Brompton Hospital in London, England as well as a fellowship in Cardiac Magnetic Resonance Imaging. She has a master’s degree in Biomedical Sciences from the Universite de Montreal with a focus in cost-effectiveness of transcatheter technology.
Dr. Anita Asgar is a full-time staff Interventional Cardiologist at the Montreal Heart Institute, and Associate Professor of Medicine at the Universite de Montreal. She specializes in transcatheter valve interventions, congenital interventions and cardiac MRI. Dr. Asgar was Co-Chair of the Canadian TAVR Guidelines and chairs the Working Group for Transcatheter Valve Therapy Quality Indicators in Canada. She has led the publication of two national quality reports for TAVR in Canada in 2016 and 2019 and was the Co-Chair of the Canadian Position statement for TAVR in 2019. She is the lead cardiologist for the transcatheter mitral/tricuspid valve program at the Montreal Heart Institute. Her research interests include the treatment and management of valvular heart disease and cost-effectiveness analysis and she is currently the Director of Transcatheter Valve Therapy Research at the Montreal Heart Institute.

Javed Butler, MD, MPH, MBA
Javed Butler, MD, MPH, MBA, is the Patrick H. Lehan Chair in Cardiovascular Research, and Professor and Chairman of the Department of Medicine at the University of Mississippi Medical Center in Jackson Mississippi. He is also Professor of Physiology. Prior to joining the University of Mississippi, he was Charles A. Gargano Professor and Director of the Division of Cardiovascular Medicine and Co-Director of the Heart Institute at Stony Brook University, New York. He had served as the director for heart failure research at Emory University and director of the heart and heart-lung transplant programs at Vanderbilt University prior to that.
He received his medical degree from the Aga Khan University and then completed residency training at Yale University, cardiology fellowship and advanced heart failure and transplant fellowships at Vanderbilt University, and cardiac imaging fellowship at the Massachusetts General Hospital at the Harvard Medical School. He has completed Master of Public Health degree from Harvard University and Master in Business Administration from Emory University.
Dr. Butler is board certified in cardiovascular medicine and advanced heart failure and transplant medicine. His research interests focus on clinical trials in patients with heart failure. He serves on several national committees for the American College of Cardiology, American Heart Association, National Institutes of Health, U.S. Food & Drug Administration, and the Heart Failure Society of America. He is the recipient of the Simon Dack Award by the American College of Cardiology as well as the Time, Feeling, and Focus Award by the American Heart Association.
Dr. Butler has authored more than 700 peer-reviewed publications. He serves on the editorial board of several peer reviewed cardiovascular journals. He has been cited numerous times in America’s Best Doctors list.

Richard Cook, BSc, MSc, MD, FRCSC
Dr. Richard Cook is a cardiac surgeon in Vancouver. He is the director of robotically-assisted and minimal-access cardiac surgery at Vancouver General Hospital. In addition to this, he is actively involved in the transcatheter valve repair and replacement programs in Vancouver. He is the outgoing chair of the cardiac surgery exam board at the Royal College of Physicians and Surgeons of Canada, and plans to use his extra free time to continue building an organic garlic farm.

Justin Ezekowitz, MBBCh, MSc, FRCPC
Dr. Justin Ezekowitz is a Professor of Medicine in the Division of Cardiology, Director of Cardiovascular Research, and Co-Director of the Canadian VIGOUR Centre at the University of Alberta. He is a cardiologist at the University of Alberta Hospital and Mazankowski Alberta Heart Institute. His research and clinical focus is on heart failure. He is involved in numerous clinical trials in heart failure as a site investigator, and on the steering or executive committee for several multicenter international trials. He is also involved in the design leadership and implementation of several investigator-initiated trials funded through governmental and non-governmental research agencies. In addition, he works with population health, registry-data and other data sources on clinically applicable research using advanced data analytics around health system change and disease risk.

Bonnie Ky, MD, MSCE
Bonny Ky is a tenured Associate Professor of Medicine and Epidemiology and physician scientist at the University of Pennsylvania. Her fundamental goals are to gain insight into the underlying mechanisms and predictors of cancer therapy cardiotoxicity, and translating this understanding to the clinical care of patients. She leads a highly active NIH-funded translational research program in cardio-oncology and is the PI of multiple investigator-initiated cohort studies and clinical trials focused on the study of the cardiotoxic effects of doxorubicin, trastuzumab, anti-angiogenic tyrosine kinase inhibitors, androgen deprivation therapy, and radiation therapy in breast, renal cell, prostate and lung cancer, and lymphoma patients. Her programmatic objectives are to understand how we can improve cardiovascular outcomes in cancer patients by determining individual patient risk, through detailed phenotyping of clinical characteristics, the social determinants of health, biologic markers, and echocardiography-derived measures of myocardial mechanics and function. She also serves as the Director for the Penn Center for Quantitative Echocardiography and is the Founding Director of the Penn Cardio-Oncology Translational Center of Excellence where she has built a strong, multi-disciplinary collaborative network comprised of highly successful basic, translational, and clinical researchers. She is an invited member of many cardio-oncology expert consensus and research groups within the NIH, FDA, American Society of Clinical Oncology, American College of Cardiology, American Heart Association, and European Society of Cardiology focused on advancing our understanding of cardiovascular disease in the growing cancer population. She is the Inaugural Editor-in-Chief of JACC: CardioOncology, and has successfully launched this important scientific and clinical resource. She has specialized expertise in cardio-oncology, epidemiology, the study of biomarkers, and imaging tools in order to understand cardiac remodeling, function, and risk prediction.

Guillaume Marquis-Gravel, MD, FRCPC
Dr. Guillaume Marquis-Gravel is an interventional cardiologist at the Montreal Heart Institute, and an assistant professor at Université de Montréal since 2020. He is a Junior 1 clinical-scientist of the Fonds de la Recherche du Québec – Santé (FRQS). He completed his medical training (M.D.), a Masters in Biomedical Sciences (M.Sc., with Honors), a residency in internal medicine, and a residency in adult cardiology (with Honors) at the Université de Montréal. He then completed a 1-year clinical fellowship in interventional cardiology at Duke University (Durham, NC, United States), followed by a 2-year clinical research fellowship at the Duke Clinical Research Institute. He is the primary author or a co-author of 65 peer-reviewed publications, including in the New England Journal of Medicine, JAMA Cardiology, the Journal of the American College of Cardiology, and Circulation, and of 4 book chapters, and has been part of the primary panel of the Canadian Cardiovascular Society guidelines on antiplatelet therapy. He is an associate editor of the Canadian Journal of Cardiology. His main research interests revolve around the antithrombotic management of acute and chronic coronary artery disease, and in the development of innovative clinical trial methods.

Mathew S. Mauer, MD
Dr. Maurer is a general internist and geriatric cardiologist with advanced training in heart failure and cardiac transplantation. He is the Arnold and Arlene Goldstein Professor of Cardiology at Columbia University Irving Medical Center, Vagelos College of Physicians & Surgeons, where directs the Clinical Cardiovascular Research Laboratory for the Elderly (CCRLE). Dr. Maurer is a member of the Advanced Cardiac Care Center at NewYork Presbyterian Hospital – Columbia Campus.
Dr. Maurer received a B.S. in biomedical science as part of the seven-year medical school program at CCNY – The Sophie Davis School of Biomedical Education, where he was awarded the Belle Zeller Scholarship. He received his M.D. degree from Mount Sinai School of Medicine and graduated Alpha Omega Alpha. He completed training in internal medicine and cardiology at NewYork Presbyterian Hospital and was Chief Medical Resident.
Dr. Maurer’s work focuses on evaluating age related changes in cardiovascular physiology in order to elucidate the mechanism that underlie the higher prevalence and incidence of cardiovascular disease in older individuals. In much of his research he has focused on the following cardiovascular syndromes – syncope, falls and their relationship to disordered blood pressure regulation; heart failure in the setting of a preserved ejection fraction including hypertrophic cardiomyopathy and cardiac amyloidosis. He has received funding from the National Institute on Aging and National Heart, Lung and Blood Institute to support his research activities.
He has published over 270 articles including peer reviewed manuscripts, reviews and book chapters. He was Chair of the American College of Cardiology’s Geriatric Cardiology Member Section, which is the largest organization dedicated to advancing the care of older adults with cardiovascular disease. He was co-chair of the Steering Committee of the ATTR-ACT trial showing tafamidis was a safe and effective therapy for transthyretin amyloid cardiomyopathy. Throughout his career, he has promulgated an approach to older adults with cardiovascular disease that offers the best of both geriatric and cardiovascular medicine in which a comprehensive holistic approach to enhance functional capacity and quality of life is at the forefront of emerging techniques to address cardiovascular physiologic derangement that disproportionately afflict older adults.

Shamir Mehta, MD, MSc, FRCPC, FACC, FESC
Dr. Shamir Mehta is the Douglas Holder Endowed Chair in Interventional Cardiology and a Professor of Medicine at McMaster University. He is Director of the Interventional Cardiology program at Hamilton Health Sciences and Senior Scientist at the Population Health Research Institute in Hamilton, Canada. He graduated from the University of Toronto’s Faculty of Medicine where he also completed internal medicine and cardiology training, followed by an interventional cardiology fellowship at the University Health Network. He completed a research fellowship and Master’s in Health Research Methodology at McMaster University and received a CIHR New Investigator Award. He was named one of Canada’s Top 40 Under 40.
He has a busy interventional and structural cardiology practice and leads the percutaneous mitral and tricuspid valve programs at HHS. He co-chairs the Canadian Cardiovascular Society Antiplatelet Therapy Guidelines. As program director of interventional cardiology, he has supervised the training over 30 interventional cardiologists in Canada and globally. His research focuses on the role of percutaneous invasive therapies in patients with acute ischemic heart disease, and the evaluation of novel antithrombotic therapies and structural heart interventions.
Dr. Mehta has published over 230 articles and holds peer-review operating grants from the CIHR, Heart and Stroke Foundation of Canada and industry. He has led large-scale trials evaluating antiplatelet therapy in patients with acute coronary syndromes, having been the Principal Investigator of the PCI-CURE study establishing the benefit of clopidogrel in patients with ACS undergoing PCI and the 25,000 patient CURRENT-OASIS 7 trial evaluating aspirin and clopidogrel dosing. He is the Principal Investigator of PREMISE, a Canadian multicenter registry of patients undergoing percutaneous mitral valve repair with the Mitraclip. He has also led landmark trials evaluating pragmatic interventions in ACS, including RIVAL, establishing the benefit of a radial artery versus femoral artery approach in patients with ACS, TIMACS evaluating optimal timing of invasive intervention in patients with ACS and the recently published COMPELTE trial evaluating a strategy of complete revascularization in patients with STEMI and multivessel disease. The COMPLETE trial was recognized by the editors of the New England Journal of Medicine as one of its Most Notable Articles of 2019.

Glen Pearson, BScPhm, PharmD, FCSHP, FCCS
Dr. Glen Pearson is a tenured Professor of Medicine in the Department of Medicine, Division of Cardiology at the University of Alberta (2012-present). He was the Associate Chair of the Health Research Ethics Boards Biomedical & Health Panels from 2012-2020 and is the current Chair of the Trainee Research Access Committee for the Faculty of Medicine & Dentistry. He is the Medical Co-Director of the Cardiac Transplant Clinic at the Mazankowski Alberta Heart Institute. He was appointed by the Minister of Health to serve as a member of the Alberta Expert Committee on Drug Evaluation & Therapeutics Committee since 2011. He has been a member of the Canadian Dyslipidemia Guidelines primary panel since 2009, served as the Vice-Chair for the 2016 CCS Dyslipidemia Guidelines and was the Co-Chair for the 2021 CCS Dyslipidemia Guidelines. He currently teaches in the Cardio-Renal Block of the first Medical Practice course for medical and dental students. He also lectures in cardiovascular pharmacotherapeutics to the both the undergraduate and graduate health professions students at the University of Alberta (PharmD, MD, and MSc/PhD graduate programs). In addition to his clinical and academic responsibilities, Dr. Pearson has an active interest in practice-based research.

Marc A. Pfeffer, MD, PhD
Dr. Marc A. Pfeffer, a graduate of Rockford College in Rockford, Illinois, received both his doctorate in physiology and biophysics and his medical degree from the University of Oklahoma in Oklahoma City. He completed his internship, residency and clinical fellowship at the Peter Bent Brigham Hospital, Harvard Medical School in Boston. Dr. Pfeffer is currently the Distinguished Dzau Professor of Medicine at Harvard Medical School, and Senior Physician in the Cardiovascular Division at the Brigham and Women’s Hospital in Boston. A noted researcher, Dr. Pfeffer, along with his late wife, Dr. Janice Pfeffer, and Eugene Braunwald MD, is credited with introducing the concept that angiotensin-converting enzyme inhibitors (ACEIs) could attenuate adverse ventricular remodelling following myocardial infarction and that this use would result in a prolongation of survival and other clinical benefits. Since this initial discovery, he has had a principal role in several practice-changing clinical outcome trials.
An internationally recognized expert in the field of cardiology, Dr. Pfeffer was recognized by Science Watch as having the most ‘Hot Papers’ (highly cited) in all of clinical medicine and was listed as one of the highly influential biomedical researchers of 1996-2011 in the European Journal of Clinical Investigation. He is the recipient of the William Harvey Award of the American Society of Hypertension, the Okamoto Award from Japan’s Vascular Disease Research Foundation, the American Heart Association Clinical Research Prize and the James B. Herrick Award. The Distinguished Scientist Awards from both the American Heart Association as well as the American College of Cardiology. The Lifetime Achievement Award from both the Heart Failure Society of America and the Heart Failure Association of the European Congress of Cardiology. The Gold Medal Award from the European Society of Cardiology in 2018. Dr. Pfeffer has Honorary Doctoral Degrees from Sahlgrenska Academy and the University of Gothenburg, Sweden and from the University of Glasgow, Scotland.

Josep Rodés-Cabau, MD, PhD
Dr. Josep Rodés-Cabau completed his medical studies at the University of Barcelona, Spain, and a residency in cardiology at the Vall d’Hebron University Hospital of Barcelona, Spain. He did a fellowship in Interventional Cardiology at the Montreal Heart Institute, Montreal, Canada and at the Institut Cardiovasculaire ParisSud, Paris, France. He is currently the director of the Catheterization and Interventional Laboratories of the Quebec Heart and Lung Institute, Quebec, Canada; Associate Professor of Medicine at Laval University, Quebec City, Canada; and Director of Research and Innovation at the Hospital Clinic of Barcelona, Barcelona, Spain. He has developed his research program in the field of interventional cardiology, with special interest in structural heart disease. He holds the Research Chair “Fondation Famille Jacques Larivière” for the Development of Structural Heart Disease Interventions (Laval University). He has published 600 articles in peer-reviewed journals, and has an H index of 102 (H index -5 years-: 88). He is among the 1% most cited scientists, and he is currently associate editor of the Journal of the American College of Cardiology.

Robert Rosenson, MD, FACC, FACP, FAHA, FNLA, FACCP
Robert S. Rosenson, MD, is Professor of Medicine at the Icahn School of Medicine at Mount Sinai, and Director of Metabolism and Lipids for the Mount Sinai Health System, New York, New York. He received his medical degree at Tulane University, New Orleans, Louisiana, and went on to complete his residency in internal medicine at Brigham and Women’s Hospital, Boston, Massachusetts, followed by a fellowship in cardiovascular medicine at The University of Chicago, Chicago, Illinois.
Dr Rosenson is a Fellow of the American College of Cardiology (FACC), American College of Physicians (FACP), College of Chest Physicians (FCCP), Fellow of the American Heart Association (FAHA) Council on Arteriosclerosis, Thrombosis, and Vascular Biology, and the AHA Council on Epidemiology and Prevention, European Society of Cardiology (FESC) and National Lipid Association (FNLA). Dr Rosenson was Global PI of the PLASMA I, PLASMA II, FRANCIS, BANTING, and two phase 2 trials with evinacumab. He is the recipient of numerous awards and honors, including the Ground-Breaking Doctors Award from Chicago magazine, and was named New York Top Doc from 2015 to 2021 and USA Top Doctor in 2019. Dr Rosenson was named recipient of the Simon Dack Award for outstanding scholarship by the Journal of the American College of Cardiology in 2015, 2016, 2017, 2019 and 2020. The International Academy of Cardiology honored him with the Jan J. Kellerman Memorial Award in 2016 for distinguished contributions in the field of cardiovascular disease prevention. In 2017, UpToDate recognized him for 20 years of Outstanding Contributions as Editor. In 2019, he was awarded the Clinician Educator Award from the National Lipid Association. He was selected by the Univesity of Toronto for the “Great Minds and Great Medicine: Isadore Rosenfeld Visiting Lectureship
He is former co-Editor in Chief for Cardiovascular Drugs and Therapy, Section Editor on Metabolic Disorders for the Journal of the American College of Cardiology, and Section Editor on Lipid Disorders for UptoDate.

John A. Spertus, MD, MPH, FACC
John Spertus is a cardiologist and the Lauer/Missouri Endowed Chair and Professor of Medicine at the University of Missouri-Kansas City, where he serves as Clinical Director of Outcomes Research at Saint Luke’s Mid America Heart Institute. He is a graduate of UCSF Medical School and completed his internal medicine, cardiology and health services training at the University of Washington. He has served on numerous national committees for the American College of Cardiology, American Heart Association, American Medical Association, National Quality Forum, Medicare and United Healthcare. His research activities led to his induction into the American Society of Clinical Investigation in 2006 and the Association of University Cardiologists in 2018, his receipt of the AHA Quality of Care and Outcomes Research Council’s Distinguished Achievement Award in 2013, QCOR’s Lifetime Achievement Award in 2015 and being named a Distinguished Scientist in 2018 by the AHA. He has been named by Thompson Reuters as one of the most influential scientists in the world in 2014 and 2015 and among their list of highly-cited authors from 2016-2019. He founded the Cardiovascular Outcomes Research Consortium and CV Outcomes, a non-profit corporation dedicated to advancing healthcare quality and outcomes research in cardiovascular disease. He is a founder of Health Outcomes Sciences, an information technology company that supports the implementation of evidence-based, personalized medicine in clinical care. Dr. Spertus and his collaborators have published over 800 peer-reviewed articles and hold 9 patents.
Dr. Spertus has devoted his career to improving the quality and patient-centeredness of care. His research focuses on methods for assessing patients’ health outcomes, measuring healthcare quality, and the use of information technology to guide medical decision-making based on risk-prediction models so that treatment can be safer, more cost-effective, evidence-based and patient-centered. He developed the Seattle Angina Questionnaire (SAQ), and the Kansas City Cardiomyopathy Questionnaire (KCCQ), which have both been translated into over 95 languages each and have become the gold standards for measuring patients’ symptoms, function and quality of life in coronary artery disease and heart failure. The KCCQ was the first patient-reported outcomes measure to ever be qualified by the FDA for heart failure. Dr. Spertus has helped design, analyze and interpret the results of numerous clinical trials, including the ISCHEMIA trial, where he led the study’s quality of life component. While he collaborates with basic scientists to illuminate the prognostic significance of genetics and biomarkers on cardiovascular outcomes, his primary focus in the translational research enterprise is at the interface of patient care. Since arriving in Kansas City, Dr. Spertus has continuously supported his research program through extramural funding and currently supports over 18 employees. His group serves as an analytic center for the ACC’s NCDR.
The ability to quantify a patient’s health status has matured rapidly over the past decade and is being tested as a measure of healthcare quality by Medicare and endorsed by ICHOM. These more standardized approaches, which measure symptoms, function, and quality of life in patients with cardiovascular disease, provide the opportunity to use these metrics as outcomes in clinical trials, tools for patient management, selection criteria for disease management programs, methods for quality assessment/improvement, and tools for allowing patients to participate in their medical decision making. The ability of physicians to base treatment decisions on predictive models, and to inform patients’ understanding of treatment options and their predicted outcomes, represents a paradigmatic shift in care that has the potential to significantly improve its value to patients and society.

Dr. Tang
Anthony Tang, MD, FRCPC
Dr. Anthony Tang is Professor of Medicine and Professor of Epidemiology & Biostatistics at Western University and Adjunct Professor of Medicine in the Faculty of Medicine at the University of Ottawa. Dr Tang is presently Staff Electrophysiologist Division of Cardiology for the London Health Sciences Centre and Chair of Cardiovascular Population Health. He obtained his MD from the University of Toronto and his clinical training in internal medicine and cardiology at the University of Ottawa. Dr. Tang obtained a Heart and Stroke Research Fellowship to receive electrophysiology research training at Duke University Medical Centre. He is member of Ontario Medical Association, Canadian Cardiovascular Society, Canadian Heart Rhythm Society, and Heart Rhythm Society (Fellow).
Dr. Tang’s clinical and research expertise is on the diagnosis and treatment of patients with cardiac arrhythmia, particular in heart failure patients. He has conducted multi-national, multicentre clinical trials for more than 20 years. The research on the addition of CRT to Implantable Cardioverter Defibrillator (ICD) and medical therapy demonstrated a reduction of total mortality and hospitalization for Heart Failure (HF) in ambulatory heart failure patients. (NEJM 2010;363(25):2385-95). This study results changed the treatment strategy of heart failure patients with compromised LV function and electrical dyssynchrony. Dr. Tang currently has two CIHR grants to conduct research that examines treatment options for patients in Atrial fibrillation with heart failure. Currently, he is the Scientific Director & CEO for the Canadian Arrhythmia Network (CANet), which is funded by the Network of Excellence (NCE) from 2015-20.
Dr. Tang is an internationally renowned researcher, has been an invited speaker at national and international meetings, and is a peer reviewer for scientific journals, as well as grant reviewer. His publication record includes over 140 peer reviewed papers, 5 book chapters and over 270 abstracts.

Jean-Francois Tanguay, MD, FRCPC, FCCS, FACC, FAHA, FESC
Dr. Tanguay is an expert in Interventional Cardiology with a strong interest in translational research. He is involved in undergraduate and postgraduate medical training and CME education. Dr. Tanguay is Director of the Interventional Cardiology Division at the MHI and Clinical Cardiologist, combining work in the emergency room, the coronary care unit, the outpatient clinic and the catheterization laboratory (1995-ongoing). He is Director of the MD-PhD and Interventional Cardiology Training Programs and professor at the Faculty of Medicine of the Université de Montréal.
His research is focus on understanding the interactions between platelets, leukocytes and endothelial cells in order to improve vascular healing. Dr. Tanguay’s investigations brought promising discoveries related to 17beta-estradiol and the specific contribution of estrogen receptors in vascular healing. During his research fellowship, Dr Tanguay studied the early prototypes of bioresorbable drug eluting stents platforms in pre-clinical and thrombosis models. With his colleagues at MHI, he performed the first coronary implantation of a drug-eluting bioresorbable scaffold (ABSORBTM) in North-America.
He has authored and co-authored more than 300 scientific publications, abstracts and books chapters. His current research interests focus on improving vascular healing, stabilizing vulnerable plaque and reducing restenosis.

George Thanassoulis, MD
Dr. Thanassoulis is the Director of Preventive and Genomic Cardiology at the MUHC and an Associate Professor of Medicine at McGill University. His clinical interests are in cardiovascular prevention, dyslipidemia (specifically lipoprotein[a]) and premature coronary artery disease. He currently runs the MUHC Family Heart Clinic for patients with premature CAD and their families with the goal of optimizing their preventive care. His research interests are in the genetics of aortic valve stenosis where he leads an international consortium investigating the role of genomic variation in this disease. He is also working on developing new approaches to optimize cardiovascular prevention in young individuals. He is the co-chair of the 2021 CCS Dyslipidemia Guideline Committee.

Richard Whitlock, MD, PhD, FRCSC
Dr. Whitlock is a Professor of Surgery at McMaster University and a practicing cardiac surgeon at Hamilton Health Sciences. He is a lead investigator at the Population Health Research Institute and the principal investigator of the LAAOS III trial, along with co-principal investigator Dr. Stuart Connolly. Dr. Whitlock holds the Canada Research Chair in Cardiovascular Surgery and a career award from the Heart and Stroke Foundation of Canada.
Through the multinational studies that he has led, which include SIRS, TRICS III, VISION Cardiac, and LAAOS III, he has established a network of over 130 collaborating cardiac surgical centres in 32 countries.

Gloria Y. Yeh, MD, MPH
Gloria Yeh, MD, MPH is Associate Professor of Medicine at Harvard Medical School (HMS), Director of Clinical Research at the Osher Center for Integrative Medicine at HMS and Brigham and Women’s Hospital, and Director of the NIH T32-funded HMS Research Fellowship in Integrative Medicine. Her research program is based in the Division of General Medicine at Beth Israel Deaconess Medical Center, where she also serves as the Division’s Director of Mind-Body Research. Dr. Yeh is an internationally recognized leader in the field of mind-body medicine, including Tai Chi, yoga, and meditation. Her research has investigated the impact of mind-body movement interventions on physiological, psychosocial, and behavioral outcomes in complex chronic illness. Dr. Yeh also serves as a member of the Academic Consortium for Integrative Medicine and Health and on the NIH National Advisory Council for Complementary and Integrative Health.

Shelley Zieroth, MD, FCCS, FHFSA (hon), FESC, FACC, FHFA, FRCPC
  Dr. Shelley Zieroth joined the Section of Cardiology at St. Boniface Hospital in Winnipeg in July 2006. She is currently a Professor in the College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, as well as Director of the Heart Failure and Heart Transplant Clinics. She is also Head of the Medical Heart Failure Program for Cardiac Sciences Manitoba.
  Dr. Zieroth attended medical school at the University of Manitoba and went on to train in Internal Medicine and Cardiology at the same centre. She completed her Postdoctoral Clinical Fellowship, specializing in Advanced Heart Failure and Cardiac Transplant, at Toronto General Hospital.
  She is involved in several heart failure clinical trials as a PI, National Lead or Executive Committee member. Her area of research examines the efficacy of new treatments including food derived bioactives, in heart failure. She is the Immediate Past President of the Canadian Heart Failure Society and on the Canadian Cardiovascular Society Primary Panels for both the Heart Failure and Heart Transplant Guidelines. She serves as Co-Chair of Canada’s largest annual heart failure meeting, HF Update and Scientific Planning Committee Chair for the Canadian Cardiovascular Congress hosted by the Canadian Cardiovascular Society. Her current passion is working with national and provincial patient advocacy groups and primary care to operationalize hub and spoke models of heart failure care.
  Dr. Zieroth is actively engaged in Social Media and promotes #cardiotwitter for its rapid access to clinical trial data, publications, and free online access to medical education. It is through this engagement Dr. Zieroth has become recognized as a global supporter and sponsor of women in medicine and cardiology.

Early Career Case Presenters (2021)

Zeeshan Ahmed, MD, FRCPC, DRCPSC, is a 3rd year Interventional Cardiology Fellow doing CTO and complex PCI training at the University of Ottawa Heart Institute. He completed his MD, Internal Medicine, Cardiology and his first year of Interventional Cardiology training at McMaster University.

David Bobrowski, MD, is a first-year internal medicine resident at the University of Toronto (ON, Canada). Prior to residency, he attended the University of Toronto for medical school and pursued his Bachelor of Health Sciences at McMaster University. He has developed an interest in cardiovascular health. He is grateful for the opportunity to present at the Toronto Ottawa Heart Summit.

Vinay Garg, MD, MSc, FRCPC, completed his BHSc at Western University in Health Sciences before attending Queen's University for medical school. He completed his internal medicine training at the University of Toronto. During his Adult Cardiology fellowship training, he also completed a Master of Science degree in Pharmacology and Toxicology at the University of Toronto. In January 2022, Dr. Garg will begin his Electrophysiology fellowship training at St. Michael's Hospital.

Ameena Meerasa, MD, FRCPC, is an endocrinologist, currently working as a Clinical Associate at the University Health Network where she is working towards her Masters at the Institute of Medical Science. Prior to that, she completed her Endocrinology & Metabolism training at the University of Ottawa and her Internal Medicine training at Dalhousie University. Her clinical interests include diabetes, obesity and metabolic disease.

Amélie Paquin, MD, MSc, FRCPC, completed her cardiology training and a Master’s degree in epidemiology at Laval University in Quebec City. She is currently a fellow at the University of Ottawa Heart Institute in echocardiography and Women’s Heart Health research. She is also doing a PhD in collaboration with Laval University, looking into the sex-specific impact of cardiometabolic risk factors on the development of cardiovascular diseases.

Anthony Poulin, MD, FRCPC, is a 3rd year interventional fellow at the Ottawa Heart Institute and his training focus on imaging and intervention for structural and aortic diseases. He will start working at the Quebec Heart and Lung Institute as a staff interventional cardiologist in July 2022. He is completing training in interventional cardiology and cardiovascular CT.

Varinder Randhawa, MD, PhD (biochemistry), has completed internal medicine, cardiology and advanced heart failure and transplant medicine training including at UofT and Cleveland Clinic where she has undertaken post-doctorate research on heart failure, heart transplant and MCS outcomes. She has contributed to numerous publications on these and other cardiovascular topics, as well as to several grants and educational programs. She serves as a trainee rep for CHFS and CCS, trainee section editor and editorial board member of CJC, and member of the CCS guidelines KT working group and ISHLT cardiogenic shock task force.

Ismail Raed Raslan, MD, MSc, FRCPC, obtained his masters in translational medicine in cardiology from the university of Alberta. Completed residency in internal medicen from McGill university. Cardiology training at the university of Toronto and chief resident. Currently a clinical fellow in Advance heart failure and transplant at the University Health Network in Toronto

Program Planning Committee (2021)

Javed Butler MD, MPH, MBA
University of Mississippi Medical Center in Jackson Mississippi

Chris Cheung, MD
Cardiac EP Fellow, University of California San Francisco
CCI Fellow, Centre for Cardiovascular Innovation

Michael Farkouh MD, FRCPC, FACC, FAHA
University of Toronto

Peter Liu MD, FRCP
University of Ottawa Heart Institute

Susanna Mak MD, PhD, FRCPC
University of Toronto

Ismail R. Raslan, MD
Cardiology Resident PGY6
University of Toronto

Sabrina Robichaud, BSc
PhD Candidate, University of Ottawa Heart Institute

Jean-Francois Tanguay, MD, FRCPC, FCCS, FACC, FAHA, FESC
Université de Montréal

Natasha Trzaskalski, MSc
PhD Candidate, University of Ottawa Heart Institute

Program Directors


Chief Scientific Officer/VP of Research, University of Ottawa Heart Institute
Professor of Medicine, University of Ottawa



Peter Munk Chair in Multinational Clinical Trials
Director, Heart and Stroke Richard Lewar Centre of Excellence
Professor of Medicine, University of Toronto


Opt-in/Opt-out of Email Lists

In compliance with anti-spam initiatives: